# Inmazeb

NDC: 61755-019
Generic name: atoltivimab, maftivimab, and odesivimab-ebgn
Labeler / Manufacturer: Regeneron Pharmaceuticals, Inc.
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: Biologic License Application
Dosage form: INJECTION, SOLUTION
Routes: INTRAVENOUS
Marketing started: 20210729

FDA application: BLA761169

## Active ingredients

- ATOLTIVIMAB: 483.3 mg/14.5mL
- MAFTIVIMAB: 483.3 mg/14.5mL
- ODESIVIMAB: 483.3 mg/14.5mL

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"61755-019"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=61755-019
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0536b6fe-6fe5-4fd6-8cc6-1b481945c1fa